Astrazeneca (AZN) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to -$0.78.
- Astrazeneca's Debt to Equity rose 271.35% to -$0.78 in Q4 2025 from the same period last year, while for Dec 2025 it was -$0.78, marking a year-over-year increase of 271.35%. This contributed to the annual value of -$0.78 for FY2025, which is 271.35% up from last year.
- According to the latest figures from Q4 2025, Astrazeneca's Debt to Equity is -$0.78, which was up 271.35% from -$0.89 recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Debt to Equity registered a high of $0.76 during Q4 2022, and its lowest value of -$2.0 during Q1 2021.
- For the 5-year period, Astrazeneca's Debt to Equity averaged around -$0.74, with its median value being -$0.93 (2023).
- As far as peak fluctuations go, Astrazeneca's Debt to Equity surged by 13575.33% in 2021, and later plummeted by 21488.32% in 2024.
- Over the past 5 years, Astrazeneca's Debt to Equity (Quarter) stood at $0.76 in 2021, then rose by 0.62% to $0.76 in 2022, then decreased by 8.01% to $0.7 in 2023, then crashed by 214.88% to -$0.81 in 2024, then increased by 2.71% to -$0.78 in 2025.
- Its last three reported values are -$0.78 in Q4 2025, -$0.89 for Q3 2025, and -$0.55 during Q2 2025.